Sign In

China Pharmahub Corp (OTC:CPHB)

WEB NEWS

All | Comments & Business Outlook | Reverse Merger Activity

Tuesday, May 22, 2012

Comments & Business Outlook

CHINA PHARMAHUB CORP.
(A DEVELOPMENT STAGE COMPANY)
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

							Cumulative for
	For the three months ended						the period from inception
	March 31,						(July 9, 2009) through
	2012			2011			March 31, 2012

Revenue	$	41,840		$	-		$	41,840

Cost of Goods		33,521			-			33,521

Gross Profit		8,319			-			8,319

Operating expenses
General and administrative		49,346			60,892			500,548
Professional fees		14,436			153,630			882,347
Depreciation expense		1,246			1,119			7,153
Total operating expenses		65,028			215,641			1,390,048

Other income(expenses)
Gain on foreign currency transactions		-			27,835			37,644
Interest expense		(421	)		-			(1,906	)
Other income		29			-			5,247
Bad debt expense		(923	)		-			(41,273	)
Loss on equity method investments		(42	)		(5,637	)		(38,118	)
Total other income/(expenses)		(1,357	)		22,198			(38,406	)

Net Loss before noncontrolling interest		(58,066	)		(193,443	)		(1,420,135	)

Noncontrolling interest		(17	)		(513	)		(1,350	)

Net loss - attributable to China Pharmahub Corp.	$	(58,049	)	$	(192,930	)	$	(1,418,785	)

Loss per common share - basic and diluted	$	(0.00	)	$	(0.01	)

Weighted-average shares outstanding - basic and diluted		16,617,483			16,482,099

Permalink

Saturday, August 7, 2010

Reverse Merger Activity

China PharmaHub Corp enters U.S. public market: Revere merger is expected to close on August 10, 2010.

Company Snapshot:

PharmaHub’s business is the identification, licensing, development and commercialization of pharmaceutical and healthcare products and technologies between the People’s Republic of China (“PRC”) and the rest of the world. (Please note that the company is less than a year old)

Industry Snapshot:

The biotech market has experienced challenges with large pharmaceutical companies having patent expirations, increased costs and risks of developing new drugs and the lack of a promising new drug pipeline. Small biotech companies have faced limited funding resources, especially in light of the difficulties currently experienced by the capital markets.
In recent years, the pharmaceutical market in the PRC has grown at a CAGR of 27% from 2006 to 2009. This represents a 13% faster growth rate than initially expected, according to IMS Health Incorporated, a company specializing in pharmaceutical market intelligence.
The pharmaceutical market is predicted to drive $40 billion in growth over the next 3 to 4 years.
With a massive population of over 1.3 billion people, and a focus on healthcare improvement with a $125 billion investment by the government, the PRC’s pharmaceutical market is expected to double by 2013. The PRC has a vast pharmaceutical market and its research and development facilities have become world-class.

Post Merger Share Calculation:

6,478,559: Pre reverse merger outstanding shares
13,766,983: Newly issued shares of Common Stock
1,478,559: Shares held in escrow

GeoTeam® best effort calculation of total post reverse merger shares assuming full conversions: 21,724,101

Financial Snapshot: TBA

Permalink